Ardelyx (ARDX) IBSRELA Data Puts Fair Value Back In Focus

Ardelyx (ARDX) put fresh clinical data in front of investors after reporting real world results for IBSRELA at the ACG 2026 meeting, which tied tenapanor use to lower gastrointestinal related healthcare visits.

The new IBSRELA data lands after a tough stretch for Ardelyx, with the share price down 39% over the past 90 days and the year to date share price return lower by 49.76%. However, the 5 year total shareholder return is still up 171.05%.

Scan beyond Ardelyx and see how other under pressure opportunities are setting up on our hand picked list of 33 high quality undervalued stocks.

After a near 50% slide this year, Ardelyx now trades with fresh IBSRELA data in hand and sentiment clearly reset. Does that reset tilt the risk reward toward buyers, or signal value traps ahead as valuation gets unpacked next?

Most Popular Narrative: 76% Undervalued

On the most followed view of Ardelyx, a fair value of $12.90 set against a last close of $3.09 points to a wide valuation gap that turns every new IBSRELA data point into a potential sentiment catalyst.

The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

See why 74 investors see Ardelyx as 76% undervalued.

Result: Fair Value of $12.90 (UNDERVALUED)

Still, the heavy reliance on tenapanor based drugs and the loss of XPHOZAH's largest payer could quickly undermine the bullish Ardelyx valuation narrative.

Find out about the key risks to this Ardelyx narrative.

Next Steps

Sentiment around Ardelyx is clearly split, with fresh data on one side and valuation doubts on the other, so move fast and weigh both. To see how those cross currents show up in the numbers and pressure points, check the 4 key rewards and 1 important warning sign.

Looking for more Ardelyx investment ideas?

Do not stop with Ardelyx. Use the Simply Wall Street Screener to compare this setup with other targeted opportunities and avoid leaving better risk reward trades on the table.

• Hunt for quality at a discount by scanning companies that screen as 33 high quality undervalued stocks before sentiment catches up to the numbers.
• Target resilience by focusing on businesses that pass our balance sheet checks through the list of solid balance sheet and fundamentals (25 results).
• Spot early stage potential by tracking lesser known stocks surfacing in the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com